Could This Tiny Device Help You Make an Extra $30k a Year?

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

VRTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.20%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $36,823,476.56

Vertex Pharmaceuticals Insider Trading History Chart

Vertex Pharmaceuticals Share Price & Price History

^$397.27

▲ +0.63 (0.16%)

As of 12/20/2024 06:51 PM ET

Days: 30 | 90 | 365

Why I'm telling friends to avoid gold stocks

From DTI | Ad

Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."

And if you’d like to get your hands on this, here you go, the complete breakdown.

Vertex Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/15/2024	David Altshuler	EVP	Sell	15	$478.56	$7,178.40	25,813
8/30/2024	Jeffrey M. Leiden	Chairman	Sell	3,784	$499.00	$1,888,216.00	9,994
8/30/2024	Sangeeta N Bhatia	Director	Sell	646	$500.00	$323,000.00	4,435
8/7/2024	Carmen Bozic	CMO	Sell	2,280	$476.75	$1,086,990.00	23,259
8/1/2024	Bruce I. Sachs	Director	Sell	5,295	$508.00	$2,689,860.00	40,000
7/24/2024	Carmen Bozic	CMO	Sell	2,280	$488.46	$1,113,688.80	25,539
7/22/2024	Reshma Kewalramani	CEO	Sell	15,202	$497.00	$7,555,394.00	106,172
7/10/2024	Carmen Bozic	CMO	Sell	2,280	$487.34	$1,111,135.20	27,819
6/26/2024	Carmen Bozic	CMO	Sell	2,280	$471.72	$1,075,521.60	30,099
6/12/2024	Carmen Bozic	CMO	Sell	2,280	$478.00	$1,089,840.00	32,379
6/12/2024	E. Morrey Atkinson, III	EVP	Sell	7,288	$478.00	$3,483,664.00	15,972
5/30/2024	Ourania Tatsis	EVP	Sell	2,350	$439.11	$1,031,908.50	53,523
5/29/2024	Carmen Bozic	CMO	Sell	2,280	$445.56	$1,015,876.80	34,659
5/28/2024	Charles F. Wagner, Jr.	CFO	Sell	3,250	$454.79	$1,478,067.50	50,387
5/24/2024	Reshma Kewalramani	CEO	Sell	1,565	$457.00	$715,205.00	121,374
5/22/2024	Bruce I. Sachs	Director	Sell	7,073	$448.00	$3,168,704.00	40,000
2/26/2024	Ourania Tatsis	EVP	Sell	354	$425.70	$150,697.80	55,804
2/20/2024	Ourania Tatsis	EVP	Sell	480	$420.79	$201,979.20	59,827
2/12/2024	Amit Sachdev	EVP	Sell	3,222	$420.24	$1,354,013.28	74,364
2/12/2024	Jeffrey M. Leiden	Chairman	Sell	2,656	$419.51	$1,114,218.56	27,644
2/12/2024	Kristen Ambrose	CAO	Sell	1,374	$420.24	$577,409.76	9,676
2/12/2024	Stuart A. Arbuckle	COO	Sell	4,295	$420.24	$1,804,930.80	75,718
1/8/2024	Jeffrey M. Leiden	Chairman	Sell	6,648	$419.07	$2,785,977.36	2,423
11/6/2023	Bruce I. Sachs	Director	Sell	11,250	$385.00	$4,331,250.00	40,000
10/31/2023	Carmen Bozic	CMO	Sell	5,651	$355.92	$2,011,303.92	34,952
10/17/2023	Carmen Bozic	CMO	Sell	5,651	$373.25	$2,109,235.75	40,603
10/17/2023	Sangeeta N Bhatia	Director	Sell	243	$375.00	$91,125.00	3,901
10/16/2023	Jeffrey M. Leiden	Chairman	Sell	12,962	$374.00	$4,847,788.00	22,425
10/6/2023	Sangeeta N Bhatia	Director	Sell	242	$360.00	$87,120.00	4,144
10/3/2023	Carmen Bozic	CMO	Sell	5,651	$345.28	$1,951,177.28	46,254
10/2/2023	Jonathan Biller	EVP	Sell	610	$346.76	$211,523.60	10,569
9/19/2023	Carmen Bozic	CMO	Sell	5,651	$351.00	$1,983,501.00	51,905
8/23/2023	Ourania Tatsis	EVP	Sell	2,500	$355.00	$887,500.00	48,637
8/9/2023	David Altshuler	EVP	Sell	63	$345.51	$21,767.13	32,038
8/9/2023	Sangeeta N Bhatia	Director	Sell	242	$345.51	$83,613.42	4,386
7/17/2023	Bruce I. Sachs	Director	Sell	11,250	$356.75	$4,013,437.50	40,000
7/17/2023	Reshma Kewalramani	CEO	Sell	7,828	$355.00	$2,778,940.00	118,906
6/15/2023	Stuart A. Arbuckle	COO	Sell	8,603	$349.00	$3,002,447.00	56,556
5/30/2023	Kristen Ambrose	CAO	Sell	289	$329.82	$95,317.98	6,838
5/30/2023	Stuart A. Arbuckle	COO	Sell	82	$329.82	$27,045.24	56,556
5/8/2023	Bastiano Sanna	EVP	Sell	2,850	$350.00	$997,500.00	32,038
5/8/2023	Jeffrey M. Leiden	Chairman	Sell	1,125	$349.00	$392,625.00	35,387
5/5/2023	Bastiano Sanna	EVP	Sell	422	$350.03	$147,712.66	34,888
5/5/2023	Jeffrey M. Leiden	Chairman	Sell	879	$349.56	$307,263.24	36,512
5/2/2023	Bastiano Sanna	EVP	Sell	1,622	$350.66	$568,770.52	38,091
5/2/2023	Jeffrey M. Leiden	Chairman	Sell	6,450	$349.89	$2,256,790.50	41,899
5/2/2023	Sangeeta N Bhatia	Director	Sell	580	$348.28	$202,002.40	4,628
4/27/2023	Reshma Kewalramani	CEO	Sell	3,317	$339.08	$1,124,728.36	126,652
4/12/2023	Bastiano Sanna	EVP	Sell	7,567	$326.70	$2,472,138.90	39,713
4/12/2023	Bruce I. Sachs	Director	Sell	21,300	$326.73	$6,959,349.00	41,210
4/4/2023	Bastiano Sanna	EVP	Sell	522	$315.81	$164,852.82	47,280
3/24/2023	Charles F. Wagner, Jr.	CFO	Sell	1,768	$305.38	$539,911.84	49,611
3/17/2023	Charles F. Wagner, Jr.	CFO	Sell	2,000	$296.39	$592,780.00	51,379
3/16/2023	Bastiano Sanna	EVP	Sell	2,746	$300.59	$825,420.14	49,268
3/13/2023	Charles F. Wagner, Jr.	CFO	Sell	2,666	$293.83	$783,350.78	53,379
3/10/2023	Charles F. Wagner, Jr.	CFO	Sell	2,088	$289.61	$604,705.68	56,045
2/27/2023	Kristen Ambrose	CAO	Sell	1,207	$287.55	$347,072.85	7,303
2/27/2023	Ourania Tatsis	EVP	Sell	354	$287.48	$101,767.92	56,805
2/27/2023	Stuart A. Arbuckle	COO	Sell	5,034	$287.47	$1,447,123.98	56,556
2/22/2023	Stuart A. Arbuckle	COO	Sell	2,401	$294.33	$706,686.33	66,304
2/13/2023	Ourania Tatsis	EVP	Sell	275	$298.99	$82,222.25	65,765
2/13/2023	Stuart A. Arbuckle	COO	Sell	4,887	$298.92	$1,460,822.04	82,003
2/6/2023	David Altshuler	EVP	Sell	1,304	$306.00	$399,024.00	68,645
1/30/2023	Lloyd Carney	Director	Sell	2,700	$320.52	$865,404.00	4,150
1/27/2023	Yuchun Lee	Director	Sell	1,429	$322.03	$460,180.87	1,875
1/25/2023	Reshma Kewalramani	CEO	Sell	10,000	$315.05	$3,150,500.00	89,598
1/25/2023	Yuchun Lee	Director	Sell	4,000	$313.96	$1,255,840.00	1,875
1/23/2023	Yuchun Lee	Director	Sell	2,129	$312.02	$664,290.58	1,875
1/18/2023	Yuchun Lee	Director	Sell	442	$312.17	$137,979.14	1,875
11/7/2022	David Altshuler	EVP	Sell	1,303	$303.04	$394,861.12	36,077
10/24/2022	Sangeeta N Bhatia	Director	Sell	621	$310.00	$192,510.00	4,040
10/18/2022	Bastiano Sanna	EVP	Sell	1,791	$300.31	$537,855.21	39,192
8/15/2022	Joy Liu	SVP	Sell	3,747	$303.90	$1,138,713.30	9,605
8/15/2022	Reshma Kewalramani	CEO	Sell	11,689	$305.06	$3,565,846.34	99,598
8/15/2022	Stuart A. Arbuckle	COO	Sell	22,173	$303.93	$6,739,039.89	45,278
8/9/2022	Joy Liu	SVP	Sell	946	$300.00	$283,800.00	13,388
8/9/2022	Ourania Tatsis	EVP	Sell	1,400	$298.97	$418,558.00	46,090
8/9/2022	Stuart A. Arbuckle	COO	Sell	5,690	$300.67	$1,710,812.30	60,996
8/8/2022	Sangeeta N Bhatia	Director	Sell	621	$293.03	$181,971.63	4,661
7/29/2022	Sangeeta N Bhatia	Director	Sell	621	$278.77	$173,116.17	5,282
7/25/2022	Jeffrey M. Leiden	Chairman	Sell	132,079	$281.38	$37,164,389.02	2,423
7/19/2022	David Altshuler	EVP	Sell	17,865	$288.65	$5,156,732.25	36,077
6/24/2022	Reshma Kewalramani	CEO	Sell	11,689	$291.30	$3,405,005.70	111,153
5/4/2022	Bastiano Sanna	EVP	Sell	36	$275.09	$9,903.24	41,660
5/2/2022	Bastiano Sanna	EVP	Sell	320	$259.16	$82,931.20	41,696
5/2/2022	Charles F. Wagner, Jr.	CFO	Sell	343	$258.83	$88,778.69	42,730
5/2/2022	Sangeeta N Bhatia	Director	Sell	737	$258.94	$190,838.78	5,903
5/2/2022	Stuart A. Arbuckle	COO	Sell	306	$263.98	$80,777.88	64,760
4/29/2022	Joy Liu	SVP	Sell	120	$275.41	$33,049.20	14,334
4/25/2022	Kristen Ambrose	CAO	Sell	327	$269.55	$88,142.85	3,496
4/18/2022	Yuchun Lee	Director	Sell	2,000	$284.23	$568,460.00	1,875
4/13/2022	Jeffrey M. Leiden	Chairman	Sell	15,789	$289.04	$4,563,652.56	74,160
4/13/2022	Yuchun Lee	Director	Sell	2,000	$287.50	$575,000.00	1,875
4/11/2022	Yuchun Lee	Director	Sell	2,000	$280.30	$560,600.00	1,875
4/7/2022	Bastiano Sanna	EVP	Sell	561	$276.18	$154,936.98	42,782
4/7/2022	Yuchun Lee	Director	Sell	2,000	$274.86	$549,720.00	1,099
4/4/2022	Bastiano Sanna	EVP	Sell	562	$267.71	$150,453.02	43,343
4/4/2022	Yuchun Lee	Director	Sell	2,000	$267.72	$535,440.00	1,875
4/1/2022	Charles F. Wagner, Jr.	CFO	Sell	2,582	$264.76	$683,610.32	43,620
3/31/2022	Margaret G. McGlynn	Director	Sell	5,000	$262.27	$1,311,350.00	1,099
3/17/2022	Charles F. Wagner, Jr.	CFO	Sell	3,171	$250.15	$793,225.65
3/17/2022	Ourania Tatsis	EVP	Sell	2,833	$250.11	$708,561.63
2/25/2022	Ourania Tatsis	EVP	Sell	325	$230.95	$75,058.75
2/18/2022	Ourania Tatsis	EVP	Sell	519	$231.00	$119,889.00
2/11/2022	David Altshuler	EVP	Sell	2,297	$235.02	$539,840.94
2/2/2022	Bastiano Sanna	EVP	Sell	1,040	$250.98	$261,019.20
2/2/2022	Charles F. Wagner, Jr.	CFO	Sell	2,944	$250.07	$736,206.08
1/28/2022	Margaret G. McGlynn	Director	Sell	5,000	$241.79	$1,208,950.00

Why I'm telling friends to avoid gold stocks

From DTI | Ad

And if you’d like to get your hands on this, here you go, the complete breakdown.

SEC Filings (Institutional Ownership Changes) for Vertex Pharmaceuticals (NASDAQ:VRTX)

90.96% of Vertex Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Vertex Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
12/19/2024	Principal Financial Group Inc.	410,359	$190.85M	0.1%	+5.6%	0.159%
12/13/2024	Lord Abbett & CO. LLC	3,279	$1.53M	0.0%	+10.1%	0.001%
12/13/2024	B. Riley Wealth Advisors Inc.	8,996	$4.14M	0.1%	-13.4%	0.003%
12/10/2024	DGS Capital Management LLC	554	$0.26M	0.1%	-19.1%	0.000%
12/6/2024	Retirement Systems of Alabama	222,705	$103.58M	0.4%	-6.9%	0.086%
12/3/2024	Oddo BHF Asset Management Sas	17,013	$7.91M	0.4%	N/A	0.007%
11/29/2024	American Trust	1,463	$0.68M	0.1%	N/A	0.001%
11/27/2024	Franklin Resources Inc.	476,833	$231.18M	0.1%	-13.7%	0.185%
11/26/2024	Decatur Capital Management Inc.	4,695	$2.18M	1.0%	-47.3%	0.002%
11/26/2024	Tri Ri Asset Management Corp	18,762	$8.73M	4.5%	N/A	0.007%
11/26/2024	Peapack Gladstone Financial Corp	2,186	$1.02M	0.0%	+5.8%	0.001%
11/25/2024	Synovus Financial Corp	11,159	$5.19M	0.1%	-1.0%	0.004%
11/25/2024	Tidal Investments LLC	11,681	$5.43M	0.1%	-2.5%	0.005%
11/25/2024	Destination Wealth Management	3,361	$1.56M	0.0%	+4.5%	0.001%
11/25/2024	Wilmington Savings Fund Society FSB	4,702	$2.19M	0.0%	N/A	0.002%
11/25/2024	Sfmg LLC	7,745	$3.60M	0.3%	-1.3%	0.003%
11/25/2024	World Investment Advisors LLC	52,206	$24.28M	0.6%	N/A	0.020%
11/25/2024	Sanctuary Advisors LLC	42,903	$19.35M	0.1%	+46.1%	0.017%
11/22/2024	Sculati Wealth Management LLC	1,445	$0.67M	0.3%	-26.0%	0.001%
11/21/2024	Anchor Investment Management LLC	1,583	$0.74M	0.1%	+1,352.3%	0.001%
11/21/2024	Te Ahumairangi Investment Management Ltd	13,339	$6.17M	1.1%	-4.0%	0.005%
11/20/2024	Morse Asset Management Inc	9,977	$4.64M	1.0%	-1.4%	0.004%
11/20/2024	Virtu Financial LLC	4,682	$2.18M	0.1%	-67.5%	0.002%
11/20/2024	Advisory Resource Group	1,970	$0.92M	0.2%	+3.2%	0.001%
11/19/2024	M&T Bank Corp	18,867	$8.78M	0.0%	-5.4%	0.007%
11/19/2024	Hohimer Wealth Management LLC	2,320	$1.08M	0.2%	+3.1%	0.001%
11/18/2024	Soltis Investment Advisors LLC	778	$0.36M	0.0%	+11.9%	0.000%
11/18/2024	Rehmann Capital Advisory Group	1,952	$0.91M	0.1%	-27.7%	0.001%
11/18/2024	TD Private Client Wealth LLC	13,687	$6.37M	0.2%	+34.3%	0.005%
11/18/2024	Arete Wealth Advisors LLC	818	$0.38M	0.0%	-44.0%	0.000%
11/18/2024	Teachers Retirement System of The State of Kentucky	96,836	$45.04M	0.4%	-1.8%	0.038%
11/18/2024	Sunbelt Securities Inc.	1,681	$0.78M	0.1%	-3.7%	0.001%
11/18/2024	Toronto Dominion Bank	134,202	$62.42M	0.1%	+2.4%	0.052%
11/18/2024	Coldstream Capital Management Inc.	4,774	$2.24M	0.0%	+13.1%	0.002%
11/18/2024	Ashford Capital Management Inc.	7,919	$3.68M	0.5%	-5.7%	0.003%
11/16/2024	Geode Capital Management LLC	5,935,888	$2.75B	0.2%	-6.2%	2.305%
11/15/2024	3Chopt Investment Partners LLC	7,037	$3.27M	1.2%	-11.4%	0.003%
11/15/2024	Brophy Wealth Management LLC	2,049	$0.95M	0.3%	N/A	0.001%
11/15/2024	Vestcor Inc	65,255	$30.35M	1.0%	+1.9%	0.025%
11/15/2024	M&T Bank Corp	18,867	$8.78M	0.0%	-5.4%	0.007%
11/15/2024	Nabity Jensen Investment Management Inc	1,348	$0.63M	0.5%	N/A	0.001%
11/15/2024	Continuum Advisory LLC	1,565	$0.76M	0.1%	-6.9%	0.001%
11/15/2024	LRI Investments LLC	835	$0.40M	0.0%	+17.3%	0.000%
11/15/2024	Peloton Wealth Strategists	2,175	$1.01M	0.4%	+278.3%	0.001%
11/15/2024	Geller Advisors LLC	2,020	$0.94M	0.1%	-27.2%	0.001%
11/15/2024	Public Employees Retirement System of Ohio	121,973	$56.73M	0.2%	-1.3%	0.047%
11/15/2024	SGL Investment Advisors Inc.	1,321	$0.64M	0.3%	N/A	0.001%
11/15/2024	EWA LLC	561	$0.27M	0.1%	+12.4%	0.000%
11/15/2024	Groupama Asset Managment	34,330	$15.97M	0.3%	+12.2%	0.013%
11/15/2024	Nomura Asset Management Co. Ltd.	154,894	$72.04M	0.2%	+4.6%	0.060%
11/15/2024	Raab & Moskowitz Asset Management LLC	1,749	$0.81M	0.2%	-2.1%	0.001%
11/15/2024	MML Investors Services LLC	48,077	$22.36M	0.1%	+27.7%	0.019%
11/15/2024	Montchanin Asset Management LLC	11,422	$5.31M	4.9%	+6.4%	0.004%
11/15/2024	Legacy Investment Solutions LLC	66	$33K	0.0%	N/A	0.000%
11/15/2024	Headinvest LLC	2,868	$1.33M	0.2%	+16.7%	0.001%
11/15/2024	Dunhill Financial LLC	58	$27K	0.0%	+70.6%	0.000%
11/15/2024	Orion Portfolio Solutions LLC	8,809	$4.10M	0.1%	-7.5%	0.003%
11/15/2024	World Investment Advisors LLC	52,206	$24.28M	0.1%	N/A	0.020%
11/15/2024	Zacks Investment Management	62,484	$29.06M	0.3%	+4.5%	0.024%
11/15/2024	Zurich Insurance Group Ltd FI	53,262	$24.77M	0.2%	-41.7%	0.021%
11/15/2024	iSAM Funds UK Ltd	1,051	$0.49M	0.3%	N/A	0.000%
11/15/2024	National Bank of Canada FI	230,498	$107.20M	0.1%	+125.0%	0.090%
11/15/2024	Castleark Management LLC	82,725	$38.47M	1.6%	+76.8%	0.032%
11/15/2024	iA Global Asset Management Inc.	41,266	$19.19M	0.3%	-2.0%	0.016%
11/15/2024	EP Wealth Advisors LLC	5,153	$2.40M	0.0%	+5.0%	0.002%
11/15/2024	Insigneo Advisory Services LLC	1,314	$0.61M	0.1%	+5.2%	0.001%
11/15/2024	Kovitz Investment Group Partners LLC	36,083	$15.43M	0.1%	+14.7%	0.014%
11/15/2024	Wellington Management Group LLP	4,798,870	$2.23B	0.4%	+17.2%	1.863%
11/15/2024	Two Sigma Advisers LP	29,400	$13.67M	0.0%	-82.9%	0.011%
11/15/2024	State Street Corp	11,816,249	$5.50B	0.2%	+0.8%	4.588%
11/15/2024	Stifel Financial Corp	94,332	$43.87M	0.0%	-2.4%	0.037%
11/15/2024	SageView Advisory Group LLC	6,099	$2.84M	0.1%	-13.0%	0.002%
11/15/2024	Quantinno Capital Management LP	19,695	$9.16M	0.1%	+36.2%	0.008%
11/15/2024	Royal London Asset Management Ltd.	363,130	$168.89M	0.4%	-1.8%	0.141%
11/15/2024	Reynders McVeigh Capital Management LLC	48,730	$22.66M	1.2%	+14.8%	0.019%
11/15/2024	Pinpoint Asset Management Ltd	8,260	$3.84M	0.8%	+3.8%	0.003%
11/15/2024	Menard Financial Group LLC	1,443	$0.67M	0.4%	N/A	0.001%
11/15/2024	Morse Asset Management Inc	10,003	$4.65M	1.0%	-1.1%	0.004%
11/15/2024	Motley Fool Asset Management LLC	11,644	$5.47M	0.3%	+5.6%	0.005%
11/15/2024	Motley Fool Wealth Management LLC	39,493	$18.37M	0.9%	-4.2%	0.015%
11/15/2024	IHT Wealth Management LLC	2,531	$1.18M	0.0%	+22.6%	0.001%
11/15/2024	Ingalls & Snyder LLC	990	$0.46M	0.0%	+6.8%	0.000%
11/15/2024	Integrated Wealth Concepts LLC	5,109	$2.38M	0.0%	+53.1%	0.002%
11/15/2024	Investment Management Corp of Ontario	23,585	$10.97M	0.2%	+12.4%	0.009%
11/15/2024	Janus Henderson Group PLC	2,516,831	$1.17B	0.6%	+4.1%	0.977%
11/15/2024	Harmony Asset Management LLC	6,917	$3.22M	1.2%	+12.7%	0.003%
11/15/2024	HighTower Advisors LLC	57,242	$26.49M	0.0%	+7.6%	0.022%
11/15/2024	Hilltop Holdings Inc.	3,143	$1.46M	0.1%	+359.5%	0.001%
11/15/2024	Chevy Chase Trust Holdings LLC	446,861	$207.83M	0.6%	-1.4%	0.174%
11/15/2024	Ascent Group LLC	10,796	$5.02M	0.4%	+19.5%	0.004%
11/15/2024	Beacon Investment Advisory Services Inc.	79,171	$36.82M	1.5%	-0.1%	0.031%
11/15/2024	Beck Capital Management LLC	2,004	$0.93M	0.2%	+1.9%	0.001%
11/15/2024	Benjamin Edwards Inc.	6,668	$3.10M	0.0%	+4,913.5%	0.003%
11/15/2024	Aureus Asset Management LLC	2,186	$1.02M	0.1%	-3.5%	0.001%
11/15/2024	Kestra Investment Management LLC	2,315	$1.08M	0.0%	+28.7%	0.001%
11/15/2024	B&L Asset Management LLC	6,134	$2.85M	1.8%	N/A	0.002%
11/15/2024	Mark Sheptoff Financial Planning LLC	11,246	$5.23M	2.8%	-1.5%	0.004%
11/15/2024	Erste Asset Management GmbH	63,514	$29.40M	0.4%	N/A	0.025%
11/14/2024	Bellevue Group AG	571,406	$265.75M	4.3%	-3.7%	0.222%
11/14/2024	BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp	43,058	$20.03M	0.1%	-13.0%	0.017%

Data available starting January 2016

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $397.27

$386.49

$401.31

50 Day Range

MA: $470.41

$396.64

$516.74

52 Week Range

Now: $397.27

$377.85

$519.88

Volume

6,202,268 shs

Average Volume

1,238,190 shs

Market Capitalization

$102.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36

Who are the company insiders with the largest holdings of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top insider shareholders include:
Reshma Kewalramani (CEO)
Stuart A Arbuckle (COO)
Amit Sachdev (EVP)
David Altshuler (EVP)
Ourania Tatsis (EVP)
Charles F Wagner Jr (CFO)
Carmen Bozic (CMO)
Bastiano Sanna (EVP)
Jeffrey M Leiden (Chairman)
Bruce I Sachs (Director)
Edward Morrow Atkinson III (EVP)
Jonathan Biller (EVP)
Kristen Ambrose (CAO)
Sangeeta N Bhatia (Director)
Lloyd Carney (Director)
Yuchun Lee (Director)
Learn More about top insider investors at Vertex Pharmaceuticals.
Who are the major institutional investors of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top institutional investors include:
State Street Corp — 4.59%
FMR LLC — 4.09%
Geode Capital Management LLC — 2.30%
Jennison Associates LLC — 2.16%
Wellington Management Group LLP — 1.86%
Loomis Sayles & Co. L P — 1.19%
Learn More about top institutional investors of Vertex Pharmaceuticals stock.
Which major investors are selling Vertex Pharmaceuticals stock?: Within the previous quarter, VRTX stock was sold by these institutional investors:
Mayflower Financial Advisors LLC
Geode Capital Management LLC
AMF Tjanstepension AB
FMR LLC
Caisse DE Depot ET Placement DU Quebec
Assetmark Inc.
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
Two Sigma Advisers LP
In the last year, company insiders that have sold Vertex Pharmaceuticals company stock include:
Reshma Kewalramani (CEO)
Stuart A Arbuckle (COO)
Amit Sachdev (EVP)
David Altshuler (EVP)
Ourania Tatsis (EVP)
Charles F Wagner Jr (CFO)
Carmen Bozic (CMO)
Bastiano Sanna (EVP)
Jeffrey M Leiden (Chairman)
Bruce I Sachs (Director)
Edward Morrow Atkinson III (EVP)
Jonathan Biller (EVP)
Learn More investors selling Vertex Pharmaceuticals stock.
Which major investors are buying Vertex Pharmaceuticals stock?: During the previous quarter, VRTX stock was acquired by institutional investors including:
Edgewood Management LLC
Jennison Associates LLC
Wellington Management Group LLP
International Assets Investment Management LLC
AustralianSuper Pty Ltd
Assenagon Asset Management S.A.
Massachusetts Financial Services Co. MA
National Bank of Canada FI